Regimen Name: Gefitinib, fluorouracil, oxaliplatin, and leucovorin (IFOX)
Origin of Name: The regimen is named for 3 of the 4 drugs it contains: gefitinib (Iressa), fluorouracil (5-FU), oxaliplatin, and leucovorin. IFOX is also known as FOLFOX (fluorouracil, leucovorin, and oxaliplatin) with gefitinib.
COMMENTS
Gefitinib was originally approved in the United States for treatment of advanced non-small-cell lung cancer (NSCLC); in 2005, distribution was limited based on subsequent data indicating that it was no more effective than best supportive care. 1 In 2012, the drug was withdrawn from the US market. 2 Response to gefitinib is dependent on a mutation of the epidermal growth factor receptor (EGFR). This mutation is present predominantly in persons of East Asian origin, females, never smokers, or persons with adenocarcinoma tumors, suggesting that the drug may be beneficial in selected subpopulations of NSCLC. [3] [4] [5] [6] [7] [8] [9] [10] In patients with colorectal cancer, response does not appear to be related to the EGFR mutation; however, response does correlate with other events such as p21 and p53 expression. Patients lacking expression of p21 are reported to have higher response rates to gefitinib than patients maintaining p21 expression and a p53 mutation. 11 These data suggest there may be a role for gefitinib in selected subpopulations of colorectal cancer.
INDICATIONS
The IFOX regimen (see Table 1 ) has been studied in advanced solid malignancies 12 and as first-line therapy in metastatic, 13, 14 advanced, 15 and refractory 16 of fluid, and drink the mixture. e. Administer the suspension through a nasogastric or gastrostomy tube, followed by 4 to 6 ounces of water.
DRUG ADMINISTRATION
A. Fluorouracil is administered as an intravenous (IV) push injection or short (5 to 15 minute) infusion followed by a 22-hour IV infusion on days 1 and 2. 
SUPPORTIVE CARE
A. Acute and Delayed Emesis Prophylaxis: The IFOX regimen is predicted to cause acute emesis in 30% to 90% of patients. [20] [21] [22] [23] [24] The studies reviewed reported grade 3 nausea or vomiting in 18% to 27% of patients. 13, 16 Prophylactic antiemetic therapy with a steroid and serotonin antagonist is recommended. [21] [22] [23] [24] One group suggests that addition of a neurokinin (NK 1 ) antagonist may be appropriate in some patients. 21 One of the following regimens is recommended: The antiemetic therapy should continue for at least 3 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid, or steroid and dopamine antagonist combination, most appropriate for follow-up therapy. 25 One of the following regimens is recommended: Patients who experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [20] [21] [22] [23] [24] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles or increasing the dose, even to very high doses, is ef fective. This approach is not recommended. 25 
C. Hypersensitivity Precautions:
Oxaliplatin is reported to cause hypersensitivity reactions in 8% to 13% of patients, with the incidence of moderate to severe reactions ranging from ,1% to 7%. The most common symptoms are flushing and swelling of the face and hands, itching, sweating, lacrimation, skin rash, hives, rigors, dyspnea, and fever. Such reactions usually occur during the second or subsequent cycles, but one study sug gests that the reactions most often occur around cycle 9 or 10. [31] [32] [33] For mild reactions, the oxaliplatin infusion is stopped and an antihistamine and a corticosteroid may be administered. Moderate to severe reactions usually require administration of parenteral corticosteroids. One report suggests that lengthening the oxaliplatin infusion time from 2 to 6 hours reduces the incidence of hypersensitivity reactions and may be appropriate for some patients. Premedication with corticosteroids and antihistamines does not prevent subsequent hypersensitivity reactions. 31 D. Hematopoietic Growth Factors: Accepted practice guidelines and pharmacoeconomic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 34, 35 Since severe (grade 3 or 4) neutropenia was reported in up to 60% of patients, and febrile neutropenia was reported in 0% to 9% of patients, in the trials reviewed, 13, 16 prophylactic use of CSFs may be appropriate in some patients receiving the IFOX regimen. E. Diarrhea: Diarrhea is a frequent consequence of protracted venous infusion of fluorouracil and is less common with bolus administration. Concomitant administration of leucovorin increases the incidence and severity of fluorouracil-induced diarrhea. Diarrhea is usually mild to moderate, responding to conventional therapy. Occasionally, the problem can be severe or dose-limiting. Patients should receive a prescription for an antidiarrheal agent for use at the onset of diarrhea. The standard recommendation is loperamide 4 mg PO at the onset of diarrhea, followed by 2 mg PO every after each unformed stool, or as often as every 2 hours for 24 hours. 36 Patients should be counseled to 37 : 1. Monitor bowel movements. 2. Treat grade 1 or 2 diarrhea (increase of less than 7 stools per day or nocturnal stools) with loperamide and oral rehydration. 3. Immediately seek advice from their physician, pharmacist, or nurse for persistent (.24 hours) grade 1 or 2 diarrhea or grade 3 diarrhea (increase of $7 stools per day or incontinence or symptoms of dehydration). G. Neurotoxicity: Oxaliplatin causes acute neurotoxicity consisting of cold-induced or -exacerbated paresthesias/dysesthesias and muscle contractions. It also causes chronic neurotoxicity that can impair quality of life. Preclinical data suggest that the acute neurotoxicity may be due to oxaliplatin's effects on voltage-dependent sodium channels and/or chelation of intracellular calcium by the oxaliplatin metabolite, oxalate. 38 Intravenous infusion of 1 g each of calcium gluconate and magnesium sulfate before and after the oxaliplatin infusion was reported to significantly reduce the incidence of neurotoxicity. [39] [40] [41] Recent data indicate this is not effective. The use of calcium gluconate and magnesium sulfate is no longer recommended. 42 
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:/ ctep.info.nih.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Atrial fibrillation (grade 3 or 4) 2% 16 ; deep vein thrombosis (grade 3 or 4) 2% 16 ; dehydration (grade 3 or 4) 22% 13 5% to 33% 13, 16 ; hyponatremia (grade 3 or 4) 2% to 7%. 13,16 F. Gastrointestinal: Anorexia (grade 2) 2%, 16 (grade 3 or 4) 2% to 7% 13, 16 ; diarrhea 65%, 15 (grade 3 or 4)
